SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Courtesy of Yuki Iwamura/AFP via Getty Images
Drug Development
U.S. Regulators Announce Plans for Monkeypox Antiviral Trial
Experts from U.S. health regulatory agencies have announced plans to conduct a clinical trial to assess the safety and efficacy of TPOXX (tecovirimat) as an antiviral for monkeypox.
August 4, 2022
 · 
2 min read
 · 
Tristan Manalac
An old man looking at camera, covering his mouth with his hand. Black and white photo.
Drug Development
Two New Triggers for Alzheimer’s Identified: What Does it Mean?
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer’s disease.
August 4, 2022
 · 
3 min read
 · 
Tristan Manalac
Pictured: Alnylam CEO Yvonne Greenstreet, Alnylam
Drug Development
Alnylam Adds Amyloidosis Candidate to Growing List of Wins
Alnylam revealed its Phase III APOLLO-B study, which showed that patisiran improves both functional capacity and quality of life in patients with ATTR amyloidosis with cardiomyopathy.
August 3, 2022
 · 
3 min read
 · 
Tristan Manalac
As Healthcare Crises Pile Up, Pharma Struggles to Meet Demand - Updated
As the world faces one public health crisis after another, it seems that pharmaceutical companies across the board are having trouble keeping up with the ever-growing need for medicines.
August 3, 2022
 · 
4 min read
 · 
Tristan Manalac
Sarah Silbiger/Getty Images
Drug Development
FDA Presses Play on Celyad and Pause on Beam for Cancer Candidates
The FDA has placed a clinical hold on Beam Therapeutics’ leukemia/lymphoma therapy and has lifted the hold on Celyad’s CAR-T candidate for colorectal cancer.
August 2, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Kazia’s Star Asset Suffers Surprise Letdown in Global Glioblastoma Study
The exact implications of the paxalisib disappointment are still unclear, though it is highly likely that the candidate will be dropped from the GBM AGILE umbrella trial.
August 2, 2022
 · 
3 min read
 · 
Tristan Manalac
Pictured: Stop sign in front of FDA headquarters/S
Drug Development
Nuvation Down to Last Drug in Pipeline After Dropping Glioma Candidate
The decision comes after the FDA put NUV-422, its candidate for high-grade gliomas, on a partial clinical hold, citing safety concerns.
August 1, 2022
 · 
2 min read
 · 
Tristan Manalac
Marengo CEO Dr. Zhen Su, M.D./Courtesy of Marengo
Business
Ipsen Invests Potential $1.6B to Turbo-Charge Marengo’s Path to the Clinic
Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
August 1, 2022
 · 
3 min read
 · 
Tristan Manalac
With Some Help, Small Canadian Biotech Could Challenge Roche’s Hold in Stroke Treatment
NervGen showed that its proprietary drug NVG-291-R, could repair the nervous system after a stroke in rodents —even when it was given seven days after the episode.
July 29, 2022
 · 
3 min read
 · 
Tristan Manalac
Monkey pox vesicles in a hand
Policy
San Francisco, New York Declare Local Health Emergencies Over Monkeypox
The measures will allow San Francisco and New York to coordinate efforts across different agencies and raise the public’s awareness to curb the spread of monkeypox.
July 29, 2022
 · 
2 min read
 · 
Tristan Manalac
Chesnot/Getty Images
Sanofi Launches HBCU Diversity Partnership, Stays Strong in Q2 as Dupixent Thrives
Sanofi released its second quarter financial report just two days after it announced its new diversity initiative with HBCU Howard University. Plus: Up-and-coming eczema biologics to shake Dupixent’s foothold
July 28, 2022
 · 
3 min read
 · 
Tristan Manalac
Stem Cell Transplant Cures Oldest HIV Patient
City of Hope revealed that the oldest person living with HIV has achieved clinical remission after undergoing stem cell transplantation at the center more than three years ago.
July 28, 2022
 · 
2 min read
 · 
Tristan Manalac
Benlysta is the first biologic to be approved for
FDA
FDA Approves First Biologic Benlysta to Treat Lupus Nephritis in Kids
FDA has approved GSK’s Benlysta (belimumab), making it the first biologic treatment for children ages 5 to 17 with lupus nephritis.
July 28, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of SOPA Images via Getty Images
Policy
DOJ Opens Probe Into Falsified Data Allegations Against Cassava
The probe will be led by investigators experienced in determining whether or not entities have defrauded consumers, investors or government agencies.
July 27, 2022
 · 
2 min read
 · 
Tristan Manalac
stop sign with black board backround
Drug Development
ObsEva Dropping Linzagolix, Plans Layoffs Following FDA Setback
On Wednesday, Swiss women’s health company ObsEva announced that it is dropping linzagolix, its leading candidate for uterine fibroids.
July 27, 2022
 · 
3 min read
 · 
Tristan Manalac
Load More